- Home
- IMNN vs COCP Comparison
IMNN vs COCP Comparison
Compare IMNN & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- COCP
- Stock Information
- Founded
- IMNN 1982
- COCP N/A
- Country
- IMNN United States
- COCP United States
- Employees
- IMNN N/A
- COCP N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- COCP Health Care
- Exchange
- IMNN Nasdaq
- COCP Nasdaq
- Market Cap
- IMNN 13.6M
- COCP 15.3M
- IPO Year
- IMNN 1985
- COCP N/A
- Fundamental
- Price
- IMNN $0.88
- COCP $1.41
- Analyst Decision
- IMNN Strong Buy
- COCP Strong Buy
- Analyst Count
- IMNN 2
- COCP 1
- Target Price
- IMNN $21.50
- COCP $7.00
- AVG Volume (30 Days)
- IMNN 115.3K
- COCP 17.3K
- Earning Date
- IMNN 05-12-2025
- COCP 05-12-2025
- Dividend Yield
- IMNN N/A
- COCP N/A
- EPS Growth
- IMNN N/A
- COCP N/A
- EPS
- IMNN N/A
- COCP N/A
- Revenue
- IMNN N/A
- COCP N/A
- Revenue This Year
- IMNN N/A
- COCP N/A
- Revenue Next Year
- IMNN N/A
- COCP N/A
- P/E Ratio
- IMNN N/A
- COCP N/A
- Revenue Growth
- IMNN N/A
- COCP N/A
- 52 Week Low
- IMNN $0.64
- COCP $1.12
- 52 Week High
- IMNN $3.65
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- IMNN 45.55
- COCP 49.03
- Support Level
- IMNN $0.82
- COCP $1.30
- Resistance Level
- IMNN $0.98
- COCP $1.47
- Average True Range (ATR)
- IMNN 0.06
- COCP 0.13
- MACD
- IMNN -0.01
- COCP 0.03
- Stochastic Oscillator
- IMNN 41.64
- COCP 79.35
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).